Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 13/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879586 | 0.88 | TAS2R8 (0.50) | TAS2R8GAABRD4 | |
| SCHEMBL13879556 | 0.82 | TAS2R8 (0.48) | TAS2R8BRD4 | |
| SCHEMBL1279666 | 0.78 | TAS2R8 (1.00) | TAS2R8 | |
| SCHEMBL13879435 | 0.76 | TAS2R8 (0.63) | TAS2R8BRD4 | |
| SCHEMBL13879519 | 0.74 | TAS2R8 (0.43) | TAS2R8BRD4 | |
| SCHEMBL13879513 | 0.73 | NPSR1 (0.56) | GAA | |
| SCHEMBL13879573 | 0.71 | GAA (0.78) | TAS2R8GAA | |
| SCHEMBL13879562 | 0.71 | TAS2R8 (0.60) | TAS2R8BRD4 | |
| SCHEMBL12408233 | 0.70 | CAPN1 (0.56) | TAS2R8GAACAPN1ITGB1ITGA4 | |
| SCHEMBL13879567 | 0.69 | GAA (0.59) | TAS2R8GAACAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | TAS2R8 4662/4885GAA 463/4885BRD4 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.